Glenmark Pharmaceuticals Ltd. (Glenmark), has launched the sacubitril + valsartan tabletsin India, for the treatment of heart failure. Marketed under the brand name ‘Sacu V™’, it must be taken twice daily under doctor’s prescription. Its approved indication is to reduce the risk of cardiovascular related deaths and hospitalisations for patients with chronic heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF).
The use of sacubitril+valsartan has anestablished role in treatment of patients with heart failure with reduced ejection fraction (HFrEF) and has been endorsed by the latest heart failure treatment guidelines in Europe4 and the USA.
On the occasion of this launch, Alok Malik, EVP & Business Head‐ India Formulations, Glenmark Pharmaceuticals Ltd., said, “We are proud to bring to the patients an advanced and affordable treatment option, which has been shown to reduce the risk of cardiovascular death or heart failure hospitalisation and to improve symptoms associated with heart failure with reduced ejection fraction (HFrEF).” Glenmark’s Sacu V™ is priced at INR 19 per tablet for adose of 50mg (sacubitril 24mg + valsartan 26mg), INR 35 per tablet for a dose of 100mg (sacubitril 49mg + valsartan 51mg), and INR 45 per tablet for a dose of 200mg (sacubitril 97mg + valsartan103mg).
